Diet-Induced Obesity Is Associated with an Impaired NK Cell Function and an Increased Colon Cancer Incidence by Ina Bähr, Vincent Goritz, Henriette Doberstein, Grit Gesine Ruth Hiller, Philip Rosenstock, Janine Jahn, Ole Pörtner, Tobias Berreis, Thomas Mueller, Julia Spielmann, Heike Kielstein

“…Previous studies showed altered Natural killer (NK) cell functions in obese individuals. Therefore, we studied the impact of an impaired NK cell functionality on the increased colon cancer risk in obesity. …”
Get full text

Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy by Fatemeh Dehghan, Yekta Metanat, Mandana Askarizadeh, Ehsan Ahmadi, Vahid Moradi

“…Although published results from preclinical and clinical studies with CAR-NK cells are promising, several bottlenecks must be unlocked to maximize the effectiveness of CAR-NK cell therapy. …”
Get full text

Extranodal natural killer/T cell lymphoma nasal type simulating osteoradionecrosis with metachronic B lymphoma in the pelvis: Case report by Frida S. Colín-Guadarrama, Violeta E. Flores-Solano, Argelia Berenice-Rodríguez, Víctor H. Toral-Rizo

“…Extranodal Natural Killer/T Cell Lymphoma Nasal Type (EN-NK/T-CL-NT) is a non-Hodgkin extranodal lymphoma of unfavorable prognosis due to its aggressive nature. …”
Get full text

Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma by Qing Zhang, Kang Tian, Jinjing Xu, Haixu Zhang, Liantao Li, Qiang Fu, Dafei Chai, Huizhong Li, Junnian Zheng

“…However, their therapeutic efficacy against solid tumors is limited. Combining CAR-T or CAR-NK cells with chemotherapeutic drugs to treat solid tumor may be a promising strategy. …”
Get full text

Enhancement of anti‐sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2‐targeted CAR by Pui Yeng Lam, Natacha Omer, Josh K. M. Wong, Cui Tu, Louisa Alim, Gustavo R. Rossi, Maria Victorova, Hannah Tompkins, Cheng‐Yu Lin, Ahmed M. Mehdi, Amos Choo, Melissa R. Elliott, Elaina Coleborn, Jane Sun, Timothy Mercer, Orazio Vittorio, Lachlan J. Dobson, Alexander D. McLellan, Andrew Brooks, Zewen Kelvin Tuong, Seth W. Cheetham, Wayne Nicholls, Fernando Souza‐Fonseca‐Guimaraes

“…Advancing immunotherapy with CAR‐NK cells. Natural killer (NK) cells modified with chimeric antigen receptors (CARs) represent a promising strategy to overcome the limitations of CAR‐T cells, particularly in solid tumours. …”
Get full text

Gastric Cancer Mesenchymal Stem Cells Inhibit NK Cell Function through mTOR Signalling to Promote Tumour Growth by Shuwei Guo, Chao Huang, Fengfeng Han, Bin Chen, Ying Ding, Yuanyuan Zhao, Zhihong Chen, Shaodi Wen, Mei Wang, Bo Shen, Wei Zhu

“…The dysfunction of natural killer (NK) cells has been increasingly reported in malignancies, especially in solid tumours. …”
Get full text

Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin by Jichao Sun, Dinglan Wu, Liuhai Zheng, Huifang Wang, Jihao Zhou, Guangwei Shi, Jingbo Ma, Yuke Jiang, Zhiyu Dong, Jiexuan Li, Yuan-Qiao He, Chengchao Xu, Zhijie Li, Jigang Wang

“…Background Chimeric antigen receptor natural killer (CAR-NK) therapy holds great promise for treating hematologic tumors, but its efficacy in solid tumors is limited owing to the lack of suitable targets and poor infiltration of engineered NK cells. …”
Get full text

FLT3 is associated with dendritic cell infiltration, tertiary lymphoid structure construction, and predict response to checkpoint inhibitors immunotherapy in solid cancers by Yongchang Tang, Hong Wang, Jiankun Zhang, Chunhui Yang, Fei Xu, Yan Song, Tianen Li, Qiangbo Zhang

“…We also found that FLT3 was positively correlated with the infiltration of NK cells, B cells, and DCs. It also positively correlated with the occurrence of apoptosis in solid cancers, but exhibited opposite roles in AML. …”
Get full text

CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma by Laura M. Moser, Laura M. Moser, Laura M. Moser, Laura M. Moser, Laura M. Moser, Catrin Heim, Sebastian E. Koschade, Sebastian E. Koschade, Sebastian E. Koschade, Sebastian E. Koschade, Sebastian E. Koschade, Philipp Wendel, Philipp Wendel, Philipp Wendel, Philipp Wendel, Süleyman Bozkurt, Sabine Harenkamp, Hermann Kreyenberg, Hermann Kreyenberg, Michael Merker, Michael Merker, Christian Münch, Christian Münch, Christian Münch, Elise Gradhand, Meike Vogler, Meike Vogler, Meike Vogler, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Evelyn Ullrich, Halvard Bönig, Halvard Bönig, Jan-Henning Klusmann, Jan-Henning Klusmann, Jan-Henning Klusmann, Jan-Henning Klusmann, Peter Bader, Peter Bader, Peter Bader, Peter Bader, Peter Bader, Winfried S. Wels, Winfried S. Wels, Winfried S. Wels, Eva Rettinger, Eva Rettinger, Eva Rettinger, Eva Rettinger, Eva Rettinger

“…IntroductionCAR-T cell therapy, though successful in hematologic malignancies, faces challenges in solid tumors due to limitations of autologous T cells. …”
Get full text

CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity by Yaojie Kong, Jingyao Li, Xueyao Zhao, Yanwei Wu, Liang Chen

“…However, the application of CAR-T cell therapy in solid tumors remains challenging. This review summarized the development of CAR-T technologies, emphasized the challenges and solutions in CAR-T cell therapy for solid tumors. …”
Get full text

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metast... by Matthew Burge, David Goldstein, Andrew Haydon, Nick Pavlakis, Charlotte Lemech, Edward Hammond, Darryn Bampton, Keith Dredge, Michael P Brown, Andrew Clouston, Nigel J Waterhouse, Amanda C Stanley, Lucie Leveque-El Mouttie, Grace M Chojnowski

Get full text

CRISPR-Cas9 in basic and translational aspects of cancer therapy by Maryam Samareh Salavatipour, Zahra Poursalehi, Negin Hosseini Rouzbahani, Sohaib Mohammadyar, Mohammad Vasei

“…Results: We have defined the basics of this technology and then mentioned some clinical and preclinical studies using this technology in the treatment of a variety of solid tumors as well as hematologic neoplasms. Finally, we described the progress made by this technology in boosting immune-mediated cell therapy in oncology, such as CAR-T cells, CAR-NK cells, and CAR-M cells. …”
Get full text

MUC2 expression modulates immune infiltration in colorectal cancer by Christophe M. Raynaud, Ayesha Jabeen, Eiman I. Ahmed, Eiman I. Ahmed, Satanay Hubrack, Apryl Sanchez, Shimaa Sherif, Ahmad A. Al-Shaibi, Bernice Lo, Bernice Lo, Jessica Roelands, Davide Bedognetti, Davide Bedognetti, Wouter Hendrickx, Wouter Hendrickx

“…By employing CRISPR-mediated MUC2 knockout, we investigated the influence of MUC2 on tumor immune infiltration and its interplay with T cells and NK cells enriched peripheral blood mononuclear cells (PBMCs) in 3D spheroid cultures.ResultsWhile MUC2 was more abundant in LS-174T cell line compared to HT-29, its knockout resulted in increased immune infiltration solely in the HT-29 cell line, but not in the LS-174T cell line. …”
Get full text

Optimising sunflower yields: insights from meta-analysis on fertilisation impact and planting strategies for enhanced crop productivity in China by Shun Li, Zongqing Liu

“…Combined fertilisers (NP, NK, NP, and NPK) enhanced yield by 29.69, 28.40, 17.35, and 41.91%, respectively. …”
Get full text

Effectiveness of Sambiloto (Andrographis paniculata) Supplementation on Antibody Titers of Newcastle Disease, Avian Influenza and Infectious Bursal Disease in Broilers by Madi Hartono, Muhammad Mirandy Pratama Sirat, Purnama Edy Santosa, Ratna Ermawati

Get full text

Increased interferon I signaling, DNA damage response and evidence of T-cell exhaustion in a patient with combined interferonopathy (Aicardi-Goutières Syndrome, AGS) and cohesinopa... by Sorina Boiu, Nikolaos Paschalidis, George Sentis, Theodora Manolakou, Andrianos Nezos, Manolis Gialitakis, Maria Grigoriou, Erato Atsali, Melpomeni Giorgi, Argirios Ntinopoulos, Clio Mavragani, Periklis Makrythanasis, Dimitrios T. Boumpas, Aggelos Banos

Get full text

Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies by Sandro Matosevic

“…Clinical responses to adoptive NK-based immunotherapy have been thwarted, however, by the profound immunosuppression induced by the tumor microenvironment, particularly severe in the context of solid tumors. …”
Get full text

The Molecular Imaging of Natural Killer Cells by Mariya Shapovalova, Sean R. Pyper MD, PhD, Branden S. Moriarity PhD, Aaron M. LeBeau PhD

“…The recent success of autologous T cell-based therapies in hematological malignancies has spurred interest in applying similar immunotherapy strategies to the treatment of solid tumors. Identified nearly 4 decades ago, natural killer (NK) cells represent an arguably better cell type for immunotherapy development. …”
Get full text

Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastases by Shih-Wen Huang, Yein-Gei Lai, Hao-Ting Liao, Chin-Ling Chang, Ruo-Yu Ma, Yung-Hsiang Chen, Yae-Huei Liou, Zhen-Qi Wu, Yu-Chen Wu, Ko-Jiunn Liu, Yen-Tsung Huang, Jen-Lung Yang, Ming-Shen Dai, Nan-Shih Liao

“…However, autologous NK cell therapy has shown limited benefit in treating patients with metastatic solid tumors. …”
Get full text

Mature tertiary lymphoid structure associated CD103+ CD8+ Trm cells determined improved anti-tumor immune in breast cancer by Qin Fang, Shuru Chen, Xiaoyue Chen, Wei Zou, Di Chen, Yukang Huang, Chucheng Wu

“…BackgroundAlthough tertiary lymphoid structures (TLS) play crucial roles in the anti-tumor immune response and are associated with favorable prognoses in many solid tumors, the precise mechanisms by which TLSs enhance anti-tumor immunity remain poorly understood. …”
Get full text